European Federation of Neurological Associations (EFNA)

Amanda WorpoleExecutive Director, EFNA

Our Vision: A better quality of life for people in Europe living with a neurological disorder.

Our MissionTo influence policy makers and legislators in Europe

To communicate with our members to achieve positive change

To establish strong partnerships and alliances

The world is living longer

A baby girl born in Japan has a 50/50 chance of living 100 years

Global ageing in the 21st century

‘The world stands on the threshold of a social transformation - even a revolution - with few parallels in humanity's past.... perhaps two-thirds of all people who have ever reached the age of 65 are alive today.’

Peter G. Peterson

European Brain Council study

The number of persons with defined disorders of the brain in Europe in 2010 The total cost per person per year related to each disease by specifying direct and indirect costs

The total cost per disorder and country

The total cost of brain disorders in all of Europe

www.europeanbraincouncil.org

Cost of Disorders of the Brain in Europe 2010Gustavsson et al. Cost of disorders of the brain in Europe 2010. Eur. Neuropsych. (2011) 21, 718-779

Cost of brain disease

•Dementia - €16,584 per patient per year;€105,163 million in total

•Parkinson’s disease - €11,153 per patient per year; €13,933 million in total

•Stroke - €7775 per patient per year; €64,053 million in total

Policy Implications for European Research

• Insufficient funding for disorders of the brain

• From a societal perspective, the return on investment in brain research far exceeds the return from any other branches of research

• FP7: Specific mention of brain research

• Horizon 2020: must address clinical and basic brain research

Policy implications for European health care

•Further increase of the burden due to the increasing trend in life expectancy in Europe

•A coordinated policy covering all disorders of the brain is needed

•Increased focus on prevention should be of high priority

Policy implications for European health educators

• Only 8% of clinical education at medical schools for psychiatry and neurology.

•Even less in other health professions

•Treatment for brain disorders have drastically improved. Increased curricula and teaching efforts are needed

Policy implications - European pharmaceutical industry

• Pharmaceutical industry moving out of Europe

• Investments in drugs for brain disappointing

• Drug development for brain disorders is declining

• Unnecessary regulatory barriers to drugs

• Social and Personal Activities•relationships with friends•pastimes and hobbies•family members•holidays/breaks

•Anxiety and Depression•mental health and well-being•Anxiety•lack of energy and motivation•depression.

The PDQ-Carer

The PDQ-Carer

•Self-care:•health•health behaviour

•Stress•feelings of impatience and anger•feelings of being undervalued•weighed down by responsibilities.

Clinical trails & medicines

• Inclusion of older people in clinical trials• ‘real life’ includes co-morbidities & polypharmacy• Side effects• Drug interactions• Protocols• Outcomes: beyond the clinical • Information for patients• Pharmacovigilance

Risk factors from conception onwards

Need to take care of our brains• Healthy diet• Stay away from tobacco• Modest alcohol intake• Avoid recreational drugs• Drink water

Thank you